133 related articles for article (PubMed ID: 22150669)
21. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer.
Gopalakrishnan S; Pandey N; Tamiz AP; Vere J; Carrasco R; Somerville R; Tripathi A; Ginski M; Paterson BM; Alkan SS
Int J Pharm; 2009 Jan; 365(1-2):121-30. PubMed ID: 18832018
[TBL] [Abstract][Full Text] [Related]
23. Mucosal drug delivery using cellulose derivatives as a functional polymer.
Suzuki Y; Makino Y
J Control Release; 1999 Nov; 62(1-2):101-7. PubMed ID: 10518641
[TBL] [Abstract][Full Text] [Related]
24. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes.
Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ
Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994
[TBL] [Abstract][Full Text] [Related]
25. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.
Yang T; Hussain A; Paulson J; Abbruscato TJ; Ahsan F
Pharm Res; 2004 Jul; 21(7):1127-36. PubMed ID: 15290851
[TBL] [Abstract][Full Text] [Related]
26. Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoter and the synthetic polymer in rats.
Murakami T; Kishimoto M; Kawakita H; Kisaki M; Kojima Y; Higashi Y; Amagase H; Fuwa T; Yata N
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():125-31. PubMed ID: 1820866
[TBL] [Abstract][Full Text] [Related]
27. Improved nasal bioavailability of elcatonin by insoluble powder formulation.
Ishikawa F; Katsura M; Tamai I; Tsuji A
Int J Pharm; 2001 Aug; 224(1-2):105-14. PubMed ID: 11472819
[TBL] [Abstract][Full Text] [Related]
28. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
29. Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device.
Charlton S; Jones NS; Davis SS; Illum L
Eur J Pharm Sci; 2007 Mar; 30(3-4):295-302. PubMed ID: 17223022
[TBL] [Abstract][Full Text] [Related]
30. Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo.
Zhang YJ; Ma CH; Lu WL; Zhang X; Wang XL; Sun JN; Zhang Q
Acta Pharmacol Sin; 2005 Nov; 26(11):1402-8. PubMed ID: 16225765
[TBL] [Abstract][Full Text] [Related]
31. Nasal delivery of insulin using bioadhesive chitosan gels.
Varshosaz J; Sadrai H; Heidari A
Drug Deliv; 2006; 13(1):31-8. PubMed ID: 16401591
[TBL] [Abstract][Full Text] [Related]
32. Paracellular drug absorption enhancement through tight junction modulation.
Lemmer HJ; Hamman JH
Expert Opin Drug Deliv; 2013 Jan; 10(1):103-14. PubMed ID: 23163247
[TBL] [Abstract][Full Text] [Related]
33. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharmacol Exp Ther; 2005 Jan; 312(1):199-205. PubMed ID: 15448170
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies.
Charlton ST; Davis SS; Illum L
J Control Release; 2007 Apr; 118(2):225-34. PubMed ID: 17261340
[TBL] [Abstract][Full Text] [Related]
35. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside.
Arnold JJ; Fyrberg MD; Meezan E; Pillion DJ
J Pharm Sci; 2010 Apr; 99(4):1912-20. PubMed ID: 19894270
[TBL] [Abstract][Full Text] [Related]
36. Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin.
Schipper NG; Verhoef JC; Romeijn SG; Merkus FW
Calcif Tissue Int; 1995 Apr; 56(4):280-2. PubMed ID: 7767838
[TBL] [Abstract][Full Text] [Related]
37. Delivery of cefotaxime to the brain via intranasal administration.
Manda P; Hargett JK; Vaka SR; Repka MA; Murthy SN
Drug Dev Ind Pharm; 2011 Nov; 37(11):1306-10. PubMed ID: 21702731
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.
Kagatani S; Shinoda T; Fukui M; Ohmura T; Hasumi S; Sonobe T
Pharm Res; 1996 May; 13(5):739-43. PubMed ID: 8860430
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Jan; 110(2):347-352. PubMed ID: 16274829
[TBL] [Abstract][Full Text] [Related]
40. CriticalSorb: a novel efficient nasal delivery system for human growth hormone based on Solutol HS15.
Illum L; Jordan F; Lewis AL
J Control Release; 2012 Aug; 162(1):194-200. PubMed ID: 22709592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
